Renal Disease: The Anesthesiologist's Perspective

Anesthesiology Clinics of North America

Volumn 24, Issue 3, 2006, Pages 523-547

  Wagener, Gebhard ^a   Brentjens, Tricia E ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CALCINEURIN INHIBITOR; CONTRAST MEDIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; FUROSEMIDE; HYPERTENSIVE FACTOR; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOTIC DIURETIC AGENT; TACROLIMUS;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANESTHESIST; BLOOD FLOW; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; GENERAL ANESTHESIA; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMATOPOIESIS; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN CLEARANCE; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE FUNCTION; NATRIURESIS; NEPHROTOXICITY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM URINE LEVEL; URINARY EXCRETION;

ANESTHETICS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; RENAL CIRCULATION; RENAL INSUFFICIENCY;

EID: 33748805764     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2006.04.001     Document Type: Review

References (96)

1. Kanwar Y.S., Liu Z.Z., Kashihara N., et al. Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 11 (1991) 390-413
2. Jacobson H.R. Functional segmentation of the mammalian nephron. Am J Physiol 241 (1981) F203-F218
3. Sands J.M., and Kokko J.P. Current concepts of the countercurrent multiplication system. Kidney Int Suppl 57 (1996) S93-S99
4. Sands J.M., and Kokko J.P. Countercurrent system. Kidney Int 38 (1990) 695-699
5. Hollenberg N.K., Epstein M., Rosen S.M., et al. Acute oliguric renal failure in man: evidence for preferential renal cortical ischemia. Medicine (Baltimore) 47 (1968) 455-474
6. Schrier R.W. Effects of adrenergic nervous system and catecholamines on systemic and renal hemodynamics, sodium and water excretion and renin secretion. Kidney Int 6 (1974) 291-306
7. Thurau K., and Boylan J.W. Acute renal success. The unexpected logic of oliguria in acute renal failure. Am J Med 61 (1976) 308-315
8. Navar L.G. Renal autoregulation: perspectives from whole kidney and single nephron studies. Am J Physiol 234 (1978) F357-F370
9. Kifor I., Moore T.J., Fallo F., et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 129 (1991) 823-831
10. Schunkert H., Ingelfinger J.R., Hirsch A.T., et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90 (1992) 1523-1529
11. Skott O., and Jensen B.L. Cellular and intrarenal control of renin secretion. Clin Sci (Lond) 84 (1993) 1-10
12. Ichikawi I., and Harris R.C. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 40 (1991) 583-596
13. Casellas D., and Moore L.C. Autoregulation and tubuloglomerular feedback in juxtamedullary glomerular arterioles. Am J Physiol 258 (1990) F660-F669
14. Goodfriend T.L., Elliott M.E., and Catt K.J. Angiotensin receptors and their antagonists. N Engl J Med 334 (1996) 1649-1654
15. Romero J.C., and Knox F.G. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension 11 (1988) 724-738
16. Myers B.D., Deen W.M., and Brenner B.M. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37 (1975) 101-110
17. Oliver J.A., Pinto J., Sciacca R.R., et al. Increased renal secretion of norepinephrine and prostaglandin E2 during sodium depletion in the dog. J Clin Invest 66 (1980) 748-756
18. Jose P.A., Eisner G.M., and Felder R.A. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11 (2002) 87-92
19. Steinhausen M., Endlich K., and Wiegman D.L. Glomerular blood flow. Kidney Int 38 (1990) 769-784
20. Holmes C.L., Landry D.W., and Granton J.T. Science review: Vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 7 (2003) 427-434
21. Holmes C.L., Landry D.W., and Granton J.T. Science Review: Vasopressin and the cardiovascular system part 2-clinical physiology. Crit Care 8 (2004) 15-23
22. Breyer M.D., and Breyer R.M. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 9 (2000) 23-29
23. Welch W.J., and Wilcox C.S. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest 89 (1992) 1857-1865
24. de Bold A.J., Borenstein H.B., Veress A.T., et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
25. Webster M.W., Sharpe D.N., Coxon R., et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 63 (1989) 217-221
26. Mattingly M.T., Brandt R.R., Heublein D.M., et al. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 46 (1994) 744-747
27. Kohan D.E. Endothelins in the normal and diseased kidney. Am J Kidney Dis 29 (1997) 2-26
28. Chou S.Y., Dahhan A., and Porush J.G. Renal actions of endothelin: interaction with prostacyclin. Am J Physiol 259 (1990) F645-F652
29. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
30. Davidson N.C., and Struthers A.D. Brain natriuretic peptide. J Hypertens 12 (1994) 329-336
31. Ito S., Carretero O.A., and Abe K. Nitric oxide in the regulation of renal blood flow. New Horiz 3 (1995) 615-623
32. Berthold H., Just A., Kirchheim H.R., et al. Interaction between nitric oxide and endogenous vasoconstrictors in control of renal blood flow. Hypertension 34 (1999) 1254-1258
33. Weihprecht H., Lorenz J.N., Schnermann J., et al. Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J Clin Invest 85 (1990) 1622-1628
34. Hansen P.B., and Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 285 (2003) F590-F599
35. Lee H.T., Xu H., Nasr S.H., et al. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 286 (2004) F298-F306
36. Pfeilschifter J., and Huwiler A. Erythropoietin is more than just a promoter of erythropoiesis. J Am Soc Nephrol 15 (2004) 2240-2241
37. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228 (2003) 1-14
38. Lameire N., Van Biesen W., and Vanholder R. Acute renal failure. Lancet 365 (2005) 417-430
39. Sladen R.N., Endo E., and Harrison T. Two-hour versus 22-hour creatinine clearance in critically ill patients. Anesthesiology 67 (1987) 1013-1016
40. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
41. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
42. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005) 1231-1238
43. Mishra J., Mori K., Ma Q., et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24 (2004) 307-315
44. Wagener G.J.M., Kim M., Mori M., et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology (2006) in press
45. Herd J.A. Cardiovascular response to stress. Physiol Rev 71 (1991) 305-330
46. O'Malley C.M., Frumento R.J., and Bennett-Guerrero E. Intravenous fluid therapy in renal transplant recipients: results of a US survey. Transplant Proc 34 (2002) 3142-3145
47. Chertow G.M. Dialysis: cost-effective "SUPPORT" for patients with acute renal failure. Am J Kidney Dis 31 (1998) 545-548 [discussion: 548-9]
48. Chertow G.M., Lazarus J.M., Paganini E.P., et al. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 9 (1998) 692-698
49. Ahlstrom A., Tallgren M., Peltonen S., et al. Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Med 31 (2005) 1222-1228
50. Palevsky P.M., Metnitz P.G., Piccinni P., et al. Selection of endpoints for clinical trials of acute renal failure in critically ill patients. Curr Opin Crit Care 8 (2002) 515-518
51. Lameire N., and Hoste E. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care 10 (2004) 468-475
52. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004) R204-R212
53. Badr K.F., and Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 319 (1988) 623-629
54. Blantz R.C. Pathophysiology of pre-renal azotemia. Kidney Int 53 (1998) 512-523
55. Alejandro V.S., Nelson W.J., Huie P., et al. Postischemic injury, delayed function and Na + /K(+)-ATPase distribution in the transplanted kidney. Kidney Int 48 (1995) 1308-1315
56. Nath K.A., and Norby S.M. Reactive oxygen species and acute renal failure. Am J Med 109 (2000) 665-678
57. Bonventre J.V., and Weinberg J.M. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14 (2003) 2199-2210
58. Lameire N.H., and Vanholder R. Pathophysiology of ischaemic acute renal failure. Best Pract Res Clin Anaesthesiol 18 (2004) 21-36
59. Nigam S., and Lieberthal W. Acute renal failure. III. The role of growth factors in the process of renal regeneration and repair. Am J Physiol Renal Physiol 279 (2000) F3-F11
60. Schrier R.W., and Wang W. Acute renal failure and sepsis. N Engl J Med 351 (2004) 159-169
61. Badr K.F., Kelley V.E., Rennke H.G., et al. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int 30 (1986) 474-480
62. Ravikant T., and Lucas C.E. Renal blood flow distribution in septic hyperdynamic pigs. J Surg Res 22 (1977) 294-298
63. Brenner M., Schaer G.L., Mallory D.L., et al. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest 98 (1990) 170-179
64. Di Giantomasso D., Morimatsu H., May C.N., et al. Intrarenal blood flow distribution in hyperdynamic septic shock: Effect of norepinephrine. Crit Care Med 31 (2003) 2509-2513
65. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25 (1997) 1279-1282
66. Holmes C.L., Patel B.M., Russell J.A., et al. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
67. Hilberman M., Myers B.D., Carrie B.J., et al. Acute renal failure following cardiac surgery. J Thorac Cardiovasc Surg 77 (1979) 880-888
68. Ip-Yam P.C., Murphy S., Baines M., et al. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 78 (1994) 842-847
69. Chertow G.M., Levy E.M., Hammermeister K.E., et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 104 (1998) 343-348
70. Chertow G.M., Lazarus J.M., Christiansen C.L., et al. Preoperative renal risk stratification. Circulation 95 (1997) 878-884
71. Conlon P.J., Stafford-Smith M., White W.D., et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 14 (1999) 1158-1162
72. de Moraes Lobo E.M., Burdmann E.A., and Abdulkader R.C. Renal function changes after elective cardiac surgery with cardiopulmonary bypass. Ren Fail 22 (2000) 487-497
73. Gamulin Z., Forster A., Morel D., et al. Effects of infrarenal aortic cross-clamping on renal hemodynamics in humans. Anesthesiology 61 (1984) 394-399
74. Gines P., Guevara M., Arroyo V., et al. Hepatorenal syndrome. Lancet 362 (2003) 1819-1827
75. Uriz J., Gines P., Cardenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2000) 43-48
76. Clive D.M., and Stoff J.S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310 (1984) 563-572
77. Oates J.A., FitzGerald G.A., Branch R.A., et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 319 (1988)
78. Schmieder R.E. Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. J Hypertens 23 (2005) 905-911
79. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
80. Zager R.A. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 20 (1992) 223-230
81. Rodicio J.L. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 35 (2000) S7-S11
82. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
83. Nash K., Hafeez A., and Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 39 (2002) 930-936
84. Liss P., Nygren A., Erikson U., et al. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 53 (1998) 698-702
85. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 53 (1998) 230-242
86. Itoh Y., Yano T., Sendo T., et al. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci 97 (2005) 473-488
87. Bellomo R., Chapman M., Finfer S., et al. Low dose dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 (2000) 2139-2143
88. Lassnigg A., Donner E., Grubhofer G., et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11 (2000) 97-104
89. Woo E.B., Tang A.T., el-Gamel A., et al. Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: science or fiction?. Eur J Cardiothorac Surg 22 (2002) 106-111
90. Halpenny M., Rushe C., Breen P., et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 19 (2002) 32-39
91. Cantarovich F., Rangoonwala B., Lorenz H., et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 44 (2004) 402-409
92. Kay J., Chow W.H., Chan T.M., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289 (2003) 553-558
93. Shyu K.G., Cheng J.J., and Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40 (2002) 1383-1388
94. Mallick N.P., and Gokal R. Haemodialysis. Lancet 353 (1999) 737-742
95. Pastan S., and Bailey J. Dialysis therapy. N Engl J Med 338 (1998) 1428-1437
96. Forni L.G., and Hilton P.J. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 336 (1997) 1303-1309